170 related articles for article (PubMed ID: 38634515)
1. Nonspecific oral medications versus anti-calcitonin gene-related peptide monoclonal antibodies for migraine: A systematic review and meta-analysis of randomized controlled trials.
Robblee J; Hakim SM; Reynolds JM; Monteith TS; Zhang N; Barad M
Headache; 2024 May; 64(5):547-572. PubMed ID: 38634515
[TBL] [Abstract][Full Text] [Related]
2. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
3. Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis.
Kokoti L; Drellia K; Papadopoulos D; Mitsikostas DD
J Neurol; 2020 Apr; 267(4):1158-1170. PubMed ID: 31919565
[TBL] [Abstract][Full Text] [Related]
4. Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis.
Drellia K; Kokoti L; Deligianni CI; Papadopoulos D; Mitsikostas DD
Cephalalgia; 2021 Jun; 41(7):851-864. PubMed ID: 33567891
[TBL] [Abstract][Full Text] [Related]
5. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
[TBL] [Abstract][Full Text] [Related]
7. The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis.
Hou M; Xing H; Cai Y; Li B; Wang X; Li P; Hu X; Chen J
J Headache Pain; 2017 Dec; 18(1):42. PubMed ID: 28389966
[TBL] [Abstract][Full Text] [Related]
8. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.
Lampl C; MaassenVanDenBrink A; Deligianni CI; Gil-Gouveia R; Jassal T; Sanchez-Del-Rio M; Reuter U; Uluduz D; Versijpt J; Zeraatkar D; Sacco S
J Headache Pain; 2023 May; 24(1):56. PubMed ID: 37208596
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
10. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
[TBL] [Abstract][Full Text] [Related]
13. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
14. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
15. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
Moskatel LS; Graber-Naidich A; He Z; Zhang N
Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
[TBL] [Abstract][Full Text] [Related]
16. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
[TBL] [Abstract][Full Text] [Related]
17. The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.
Cohen F; Yuan H; DePoy EMG; Silberstein SD
Neurotherapeutics; 2022 Apr; 19(3):922-930. PubMed ID: 35426060
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis.
Alasad YW; Asha MZ
Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
Charles AC; Digre KB; Goadsby PJ; Robbins MS; Hershey A;
Headache; 2024 Apr; 64(4):333-341. PubMed ID: 38466028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]